ITGAX and polycystic ovary syndrome: BM-hMSC treatment significantly downregulated Il6 (0.39 ± 0.04 fold), Il1b (1.0 ± 0.41 fold), Ccl2 (0.43 ± 0.02 fold), and Cd11c (0.45 ± 0.05 fold) expression in the fat tissue of BM-hMSC-treated PCOS mice versus that of untreated PCOS mice (Fig. 6g).